Max Reinhardt - Apr 18, 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
President, Rest of World
Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
Apr 18, 2022
Transactions value $
-$458,241
Form type
4
Date filed
4/20/2022, 08:25 PM
Previous filing
Jul 6, 2021
Next filing
Apr 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Options Exercise $532K +12.5K +71.43% $42.54 30K Apr 18, 2022 Direct F1
transaction PCRX Common Stock Sale -$658K -8.94K -29.8% $73.55 21.1K Apr 18, 2022 Direct F1, F2
transaction PCRX Common Stock Options Exercise $532K +12.5K +59.36% $42.54 33.6K Apr 19, 2022 Direct F1
transaction PCRX Common Stock Sale -$673K -9.32K -27.77% $72.25 24.2K Apr 19, 2022 Direct F1, F2, F3
transaction PCRX Common Stock Options Exercise $532K +12.5K +51.57% $42.54 36.7K Apr 20, 2022 Direct F1
transaction PCRX Common Stock Sale -$722K -9.76K -26.58% $73.99 27K Apr 20, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -12.5K -8.33% $0.00 138K Apr 18, 2022 Common Stock 12.5K $42.54 Direct F4
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -12.5K -9.09% $0.00 125K Apr 19, 2022 Common Stock 12.5K $42.54 Direct F4
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -12.5K -10% $0.00 113K Apr 20, 2022 Common Stock 12.5K $42.54 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2 Represents shares sold by the reporting person to cover the (i) exercise price of stock options and (ii) tax obligations due upon the exercise of such stock options.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.01 to $72.55, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.